Method of treating humans with opioid formulations having extend

Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

424458, 424461, 424462, 424490, 424495, 424497, 514282, A61K 958, A61K 960

Patent

active

061433225

ABSTRACT:
Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37.degree. C. of from about 12.5% to about 42.5% (by wt) opioid released after 1 hour, from about 25% to about 65% (by wt) opioid released after 2 hours, from about 45% to about 85% (by wt) opioid released after 4 hours, and greater than about 60% (by wt) opioid released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of said opioid analgesic obtained in-vivo occurs from about 2 to about 8 hours after administration of the dosage form.

REFERENCES:
patent: 2738303 (1956-03-01), Blythe
patent: 3634584 (1972-01-01), Poole
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3870790 (1975-03-01), Lowey et al.
patent: 3916889 (1975-11-01), Russell
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4063064 (1977-12-01), Saunders et al.
patent: 4088864 (1978-05-01), Theeuwes et al.
patent: 4132753 (1979-01-01), Blichare et al.
patent: 4377568 (1983-03-01), Chopra
patent: 4385078 (1983-05-01), Onda et al.
patent: 4389393 (1983-06-01), Schor et al.
patent: 4421736 (1983-12-01), Walters
patent: 4443428 (1984-04-01), Oshlack
patent: 4464378 (1984-08-01), Hussain
patent: 4483847 (1984-11-01), Augart
patent: 4520172 (1985-05-01), Lehmann et al.
patent: 4548990 (1985-10-01), Mueller et al.
patent: 4557925 (1985-12-01), Lindahl et al.
patent: 4600645 (1986-07-01), Ghebre-Sellassie et al.
patent: 4609542 (1986-09-01), Panoz et al.
patent: 4708874 (1987-11-01), De Haan et al.
patent: 4728513 (1988-03-01), Ventouras
patent: 4797410 (1989-01-01), El-Fakahany
patent: 4806337 (1989-02-01), Snipes et al.
patent: 4828836 (1989-05-01), Elger et al.
patent: 4834984 (1989-05-01), Goldie et al.
patent: 4834985 (1989-05-01), Elger et al.
patent: 4844907 (1989-07-01), Elger et al.
patent: 4844909 (1989-07-01), Goldie et al.
patent: 4861598 (1989-08-01), Oshlack
patent: 4894234 (1990-01-01), Sharma et al.
patent: 4935246 (1990-06-01), Ahrens
patent: 4970075 (1990-11-01), Oshlack
patent: 4983730 (1991-01-01), Domeshek et al.
patent: 4990341 (1991-02-01), Goldie et al.
patent: 5007790 (1991-04-01), Shell
patent: 5019397 (1991-05-01), Wong et al.
patent: 5023089 (1991-06-01), Sakamoto et al.
patent: 5024842 (1991-06-01), Edgren et al.
patent: 5026560 (1991-06-01), Makino et al.
patent: 5030400 (1991-07-01), Danielsen et al.
patent: 5068110 (1991-11-01), Fawzi et al.
patent: 5071646 (1991-12-01), Malkowska
patent: 5122384 (1992-06-01), Paradissis et al.
patent: 5126145 (1992-06-01), Evenstad et al.
patent: 5132142 (1992-07-01), Jones et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5167964 (1992-12-01), Muhammed et al.
patent: 5169645 (1992-12-01), Shukla et al.
patent: 5178868 (1993-01-01), Malmqvist et al.
patent: 5196203 (1993-03-01), Boehm
patent: 5202128 (1993-04-01), Morella et al.
patent: 5206030 (1993-04-01), Wheatley et al.
patent: 5219575 (1993-06-01), Bommel et al.
patent: 5248516 (1993-09-01), Wheatley et al.
patent: 5258436 (1993-11-01), Wheatley et al.
patent: 5266331 (1993-11-01), Oshlack et al.
patent: 5273760 (1993-12-01), Oshlack et al.
patent: 5283065 (1994-02-01), Doyon et al.
patent: 5286493 (1994-02-01), Oshlack et al.
patent: 5292461 (1994-03-01), Juch et al.
patent: 5321012 (1994-06-01), Mayer et al.
patent: 5330766 (1994-07-01), Morella et al.
patent: 5378474 (1995-01-01), Morella et al.
patent: 5384130 (1995-01-01), Kamada
patent: 5411745 (1995-05-01), Oshlack et al.
patent: 5456923 (1995-10-01), Nakamichi et al.
patent: 5460826 (1995-10-01), Merrill et al.
patent: 5472712 (1995-12-01), Oshlack et al.
patent: 5500227 (1996-03-01), Oshlack et al.
patent: 5502058 (1996-03-01), Mayer et al.
patent: 5508042 (1996-04-01), Oshlack et al.
patent: 5520931 (1996-05-01), Persson et al.
patent: 5549912 (1996-08-01), Oshlack et al.
patent: 5580578 (1996-12-01), Oshlack et al.
patent: 5593695 (1997-01-01), Merrill et al.
patent: 5601842 (1997-02-01), Bartholomaeus
patent: 5614218 (1997-03-01), Olsson
patent: 5629011 (1997-05-01), Illum
patent: 5637320 (1997-06-01), Bourke et al.
patent: 5656295 (1997-08-01), Oshlack et al.
patent: 5667805 (1997-09-01), Merrill et al.
patent: 5670172 (1997-09-01), Buxton et al.
patent: 5672360 (1997-09-01), Sackler et al.
patent: 5681585 (1997-10-01), Oshlack et al.
patent: 5843480 (1998-12-01), Miller et al.
patent: 5849240 (1998-12-01), Miller et al.
patent: 5879705 (1999-03-01), Heafield et al.
patent: 5891471 (1999-04-01), Miller et al.
patent: 5965163 (1999-10-01), Miller et al.
patent: 5968551 (1999-10-01), Oshlack et al.
Abraham Sunshine, et al., "Analgesic oral efficacy of tramadol hydrochloride in postoperative pain," Clin. Pharmacol. Ther., Jun. 1992, pp. 740-746.
E. Buebler, "Medikamentose Schmerztherapie: Kriterien, Moglichkeiten, Risken," Therapiewoche Osterreich, 72, 2 (1992), pp. 90-96, with English translation.
Geoffrey K. Gourlay, Ph.D., et al., "Influence of a high-fat meal on the absorption of morphine from oral solutions," Clin. Pharmacol. Ther., Oct. 1989, pp. 463-468.
Robert Kaiko, et al., "A Single-Dose Study Of The Effect Of Food Ingestion And Timing Of Dose Administration On The Pharmacokinetic Profile Of 30-MG Sustained-Release Morphine Sulfate Tablets," Current Therapeutic Research, vol. 47, No. 5, May 1990, pp. 869-878.
Geoffrey K. Gourlay, Ph.D., "The Reproducibility of Bioavailability of Oral Morphine from Solution Under Fed and Fasted Conditions," Journal of Pain and Sympton Management, vol. 6., No. 7, Oct. 1991, pp. 431-436.
Robert F. Kaiko, et al., "Controlled-Release Morphine Bioavailability (MS Contin Tablets) in the Presence and Absence of Food," The Hospice Journal, vol. 6(4) 1990, pp. 17-30.
N. Yokokawa, et al., "Relationship between plasma concentration of morphine and analgesic effectiveness," Postgrad Med J, (1991) 67 (Suppl. 2) pp. 550-554.
Physicians Desk Reference 1994, 48.sup.th Edition, pp. 1821-1824.
D.L. Munday, "Changes in Drug Release Rate 2, Effect of Temperature and Relative Humidity on Polymeric Film Coatings," 5.sup.th Cong. Int. Tech. Pharm., 1989, vol. 2, pp. 55-60.
A Protocol for a clinical study entitled "A Randomized, Double-Blind, Parallel-Group Study comparing the Efficacy and Safety of Kapanol.RTM. to MsContin.RTM. in the Management of Patients with Moderate to Severe Cancer Pain" ("the Protocol"). The date of the Protocol is indicated as Feb. 10, 1992 and it bears COD No. 14556. The sponsor of the study is indicated to be Faulding Pharmaceuticals, an Australian company.
Certain Patient Diary Cards, Drug Disposition Records, Case Reports Forms and a listing which apparently correlates patient randomization number with the treatment of dosing regimen assigned to each patient.
Patient consent forms, apparently for four study participants.
Certain documents regarding Institutional Review Board Approval for the Faulding-sponsored study.
Investigator Agreements between the study organizers and certain of the principal investigators.
Abstracts from the Twelfth Annual Congress of the Oncology Nursing Society, May 1987.
J. Lapin et al., "Cancer Pain Management with a Controlled Release Oral Morphine Preparation," Journ. Of Pain and Sympton Manag., v 4 (3), pp. 146-151, 1989.
J. Lapin et al., "Guidelines for use of Controlled Release Oral Morphine in Cancer pin Management," Cancer Nursing, v 12 (4), pp. 202-208, 1989.
R.F. Kaiko, "The Pre-and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets): A Review of the Published Literature," Medical Department, The Purdue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989).
H.F. Slowey et al., "Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain," Anaesthesia, 1985, vol. 40, pp. 438-440.
MS Contin--Frequency of

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method of treating humans with opioid formulations having extend does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating humans with opioid formulations having extend, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating humans with opioid formulations having extend will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1638202

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.